472 related articles for article (PubMed ID: 34482189)
21. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Renal Toxicity: Illustrative Case and Review.
Sise ME; Seethapathy H; Reynolds KL
Oncologist; 2019 Jun; 24(6):735-742. PubMed ID: 30902916
[TBL] [Abstract][Full Text] [Related]
22. Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes.
Meraz-Muñoz A; Amir E; Ng P; Avila-Casado C; Ragobar C; Chan C; Kim J; Wald R; Kitchlu A
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32601079
[TBL] [Abstract][Full Text] [Related]
23. Incidence and Prediction of Immune Checkpoint Inhibitor-related Nephrotoxicity.
Sorah JD; Rose TL; Radhakrishna R; Derebail VK; Milowsky MI
J Immunother; 2021 Apr; 44(3):127-131. PubMed ID: 32925564
[TBL] [Abstract][Full Text] [Related]
24. Cohort study on immune checkpoint inhibitor-associated acute kidney injury: Incidence, risk factors, and management strategies.
Panich J; Irwin C; Bissonette A; Elkhidir S; Lodhi F; Folz C; Lee J; Pulipati S; Fatima Z; Gopinath P; Blonsky R; Abboud Leon C; Kattamanchi S
J Oncol Pharm Pract; 2024 Mar; 30(2):286-294. PubMed ID: 37125423
[TBL] [Abstract][Full Text] [Related]
25. Immune-related adverse events and immune checkpoint inhibitor tolerance on rechallenge in patients with irAEs: a single-center experience.
Bhatlapenumarthi V; Patwari A; Harb AJ
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2789-2800. PubMed ID: 33774736
[TBL] [Abstract][Full Text] [Related]
26. The 1-year decline in estimated glomerular filtration rate (eGFR) after radical nephrectomy in patients with renal masses and matched living kidney donors is the same.
Hew MN; Opondo D; Cordeiro ER; van Donselaar-van der Pant KA; Bemelman FJ; Idu MM; de la Rosette JJ; Laguna MP
BJU Int; 2014 May; 113(5b):E49-55. PubMed ID: 24053637
[TBL] [Abstract][Full Text] [Related]
27. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis.
Hussaini S; Chehade R; Boldt RG; Raphael J; Blanchette P; Maleki Vareki S; Fernandes R
Cancer Treat Rev; 2021 Jan; 92():102134. PubMed ID: 33302134
[TBL] [Abstract][Full Text] [Related]
28. Acute kidney injury in patients receiving immune checkpoint inhibitors: a retrospective real-world study.
Lumlertgul N; Vassallo P; Tydeman F; Lewis N; Hobill A; Weerapolchai K; Nordin NZ; Seylanova N; Martin L; Cennamo A; Wang Y; Rigg A; Shaunak N; Ostermann M
Eur J Cancer; 2023 Sep; 191():112967. PubMed ID: 37499561
[TBL] [Abstract][Full Text] [Related]
29. Comparing Changes in Renal Function After Radical Surgery for Upper Tract Urothelial Carcinoma and Renal Cell Carcinoma.
Singla N; Hutchinson R; Menegaz C; Haddad AQ; Jiang L; Sagalowsky AI; Cadeddu JA; Lotan Y; Margulis V
Urology; 2016 Oct; 96():44-53. PubMed ID: 27443467
[TBL] [Abstract][Full Text] [Related]
30. Infectious complications of immune checkpoint inhibitors in solid organ malignancies.
Ross JA; Komoda K; Pal S; Dickter J; Salgia R; Dadwal S
Cancer Med; 2022 Jan; 11(1):21-27. PubMed ID: 34873868
[TBL] [Abstract][Full Text] [Related]
31. Durable response after immunotherapy discontinuation for delayed and severe immune-related adverse events: a case report.
Pesola G; Murianni V; Rebuzzi SE; Banna GL; Cerbone L; Catalano F; Borea R; Gandini A; Cremante M; Puglisi S; Trovato F; Fornarini G
Immunotherapy; 2021 Dec; 13(17):1379-1386. PubMed ID: 34743545
[TBL] [Abstract][Full Text] [Related]
32. Variable Expression of Programmed Cell Death Protein 1-Ligand 1 in Kidneys Independent of Immune Checkpoint Inhibition.
Hakroush S; Kopp SB; Tampe D; Gersmann AK; Korsten P; Zeisberg M; Tampe B
Front Immunol; 2020; 11():624547. PubMed ID: 33552089
[TBL] [Abstract][Full Text] [Related]
33. Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab.
Ishihara H; Takagi T; Kondo T; Homma C; Tachibana H; Fukuda H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
Urol Oncol; 2019 Jun; 37(6):355.e21-355.e29. PubMed ID: 30935847
[TBL] [Abstract][Full Text] [Related]
34. A Nomogram to Predict Significant Estimated Glomerular Filtration Rate Reduction After Robotic Partial Nephrectomy.
Martini A; Cumarasamy S; Beksac AT; Abaza R; Eun DD; Bhandari A; Hemal AK; Porter JR; Badani KK
Eur Urol; 2018 Dec; 74(6):833-839. PubMed ID: 30224195
[TBL] [Abstract][Full Text] [Related]
35. Hyperprogressive Disease in Patients With Urothelial Carcinoma or Renal Cell Carcinoma Treated With PD-1/PD-L1 Inhibitors.
Hwang I; Park I; Yoon SK; Lee JL
Clin Genitourin Cancer; 2020 Apr; 18(2):e122-e133. PubMed ID: 31837940
[TBL] [Abstract][Full Text] [Related]
36. Case Report: Successful treatment of late-onset immune checkpoint inhibitor-associated membranous nephropathy in a patient with advanced renal cell carcinoma.
Ratanasrimetha P; Reddy VD; Kala J; Tchakarov A; Glass WF; Msaouel P; Lin JS
Front Immunol; 2022; 13():898811. PubMed ID: 35967405
[TBL] [Abstract][Full Text] [Related]
37. Immune-Related Adverse Events and Clinical Outcomes in Advanced Urothelial Cancer Patients Treated With Immune Checkpoint Inhibitors.
Sanda GE; Shabto JM; Goyal S; Liu Y; Martini DJ; Nazha B; Brown JT; Yantorni LB; Anne Russler G; Caulfield S; Joshi SS; Narayan VM; Kissick H; Ogan K; Master VA; Carthon BC; Kucuk O; Bilen MA
Oncologist; 2023 Dec; 28(12):1072-1078. PubMed ID: 37285524
[TBL] [Abstract][Full Text] [Related]
38. Acute kidney injury following coronary angiography: a nationwide study of incidence, risk factors and long-term outcomes.
Helgason D; Long TE; Helgadottir S; Palsson R; Sigurdsson GH; Gudbjartsson T; Indridason OS; Gudmundsdottir IJ; Sigurdsson MI
J Nephrol; 2018 Oct; 31(5):721-730. PubMed ID: 30187381
[TBL] [Abstract][Full Text] [Related]
39. Recent advances in immune checkpoint inhibitors in the treatment of urothelial carcinoma: A review.
Kato M; Uchida J
Int J Urol; 2023 Dec; 30(12):1068-1077. PubMed ID: 37602512
[TBL] [Abstract][Full Text] [Related]
40. Immune checkpoint inhibitor-associated acute kidney injury in patients with cancer: a systematic review and meta-analysis of risk factors.
Yan H; Tang M; Zhu W; Yang Y
Clin Exp Nephrol; 2023 Jul; 27(7):603-612. PubMed ID: 37014535
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
